Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India Saint-Herblain (France), Pune, (India), December 19, 2024 – Valneva SE (“Valneva” or “the...
Valneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of India Saint-Herblain (France), Pune, (Inde), le 19 décembre 2024 –...
Saint-Herblain (France), Pune, (India), December 19, 2024 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest...
VALNEVA - Declaration of shares and voting rights: November 30, 2024 VALNEVA Declaration of shares and voting rights November 30, 2024______________________________________________________________...
Déclaration d'actions et de droits de vote de la société Valneva SE - novembre 2024 VALNEVA Déclaration d’actions et de droits de vote 30 novembre 2024________________________________________...
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq:...
Valneva annonce la publication dans le British Medical Journal d’un article sur l’impact sanitaire et économique mondial du chikungunya Saint-Herblain (France), le 4 décembre 2024 – Valneva SE...
Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the publication of an article on the global health and...
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Antibody levels remained high at 96% seroresponse in line with the two-year...
Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.089 | 4.85013623978 | 1.835 | 2.2 | 1.726 | 792265 | 1.89149371 | DE |
4 | -0.136 | -6.60194174757 | 2.06 | 2.2 | 1.726 | 841779 | 1.89395435 | DE |
12 | -0.836 | -30.2898550725 | 2.76 | 2.804 | 1.726 | 592735 | 2.20762038 | DE |
26 | -1.244 | -39.2676767677 | 3.168 | 3.93 | 1.726 | 561816 | 2.71447485 | DE |
52 | -2.926 | -60.3298969072 | 4.85 | 4.996 | 1.726 | 553890 | 3.20386008 | DE |
156 | -23.716 | -92.496099844 | 25.64 | 26.9 | 1.726 | 558965 | 8.23702244 | DE |
260 | -0.626 | -24.5490196078 | 2.55 | 29.7 | 1.726 | 682926 | 10.81909554 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約